Oxford Vacmedix
Oxford
About Oxford Vacmedix
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Dr Shisong Jiang - Recombinant Overlapping Peptides (ROP). These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical. Immunotherapy is effective by activating the immune system to attack tumours directly thus reducing the need for invasive treatments such as chemo and radiotherapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $12.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2018)
- Website: oxfordvacmedix.com
- Phone: [email protected]
Industries & Categories
Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/oxford-vacmedix-4890 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.